Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

Patrick Ott, MD, PhD
Published: Thursday, Jul 06, 2017



Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.

In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.

The overall survival was promising, says Ott, with durable responses observed.
 


Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.

In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.

The overall survival was promising, says Ott, with durable responses observed.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x